Market Overview - The FTSE China A50 Index component stocks showed a mixed performance with bank stocks rising in the afternoon while insurance stocks continued to decline [1][5]. Banking Sector - Bank stocks generally performed well, contributing to the positive movement in the FTSE China A50 Index [1]. Insurance Sector - Major insurance companies such as China Pacific Insurance, China Life Insurance, and Ping An Insurance experienced declines in their stock prices, with China Pacific Insurance down by 1.05%, China Life down by 0.52%, and Ping An down by 1.42% [3]. Alcohol Industry - In the alcohol sector, Kweichow Moutai saw a slight increase of 0.48%, while Shanxi Fenjiu and Wuliangye experienced declines of 0.37% and 0.83% respectively [3]. Semiconductor Industry - The semiconductor companies showed varied results, with North Huachuang increasing by 2.72%, while Cambrian and Haiguang Information saw minor declines [3]. Automotive Sector - In the automotive sector, BYD's stock fell by 3.39%, while Great Wall Motors and China Railway High-speed experienced minor declines and increases respectively [3]. Shipping and Oil Industry - China COSCO Shipping saw a slight increase of 0.53%, while Sinopec and PetroChina experienced minor declines [3]. Coal and Battery Industry - China Shenhua's stock decreased by 0.27%, while Ningde Times (CATL) saw a decline of 0.83% [3]. Power and Financial Sector - Longyuan Power and China Nuclear Power had mixed results, with Longyuan Power increasing by 0.74% and China Nuclear Power declining by 3.63% [4]. Food and Beverage Sector - The food and beverage sector showed declines, with companies like Haitian Flavor Industry and Zhongtai Securities experiencing notable decreases [4]. Consumer Electronics and Pharmaceutical Sector - The consumer electronics sector saw a slight increase in stocks like Luxshare Precision, while pharmaceutical companies like Hengrui Medicine experienced a decline [4]. Logistics and Medical Equipment - The logistics sector, represented by SF Holding, saw a minor decline, while medical equipment company Mindray Medical also experienced a decrease [4]. Non-ferrous Metals and Communication Services - Zijin Mining and China Communications Construction had mixed performances, with Zijin Mining showing a slight decline [4].

Core Insights - The article discusses the emergence of Ecnoglutide, a new GLP-1 receptor agonist developed by a team led by Professor Ji Linong from Peking University People's Hospital, which poses a challenge to the market dominance of Novo Nordisk's Semaglutide in the weight loss drug sector [1][4]. Company Developments - Ecnoglutide has shown impressive results in its Phase III clinical trial (SLIMMER), with over 92.8% of participants achieving effective weight loss and an average weight reduction of 15.1% over 48 weeks [3][4]. - The trial involved 664 participants across 36 centers in China, making it the largest sample size for a weight loss drug trial in the country [3]. - The drug has entered the market application stage, indicating a potential for commercialization soon [4]. Market Landscape - The global GLP-1 weight loss drug market is projected to exceed $150 billion by 2025, with Novo Nordisk's Semaglutide leading the market, generating $8 billion in Q1 2025, a 31% year-on-year increase [5]. - Other companies, including Hengrui Medicine, East China Pharmaceutical, and others, are actively developing weight loss drugs, with some products already in Phase II or III clinical trials [2][6]. Competitive Dynamics - Ecnoglutide's clinical trial results suggest a significant competitive edge over existing products, with a higher effective weight loss rate compared to similar drugs [3][4]. - The article highlights the potential for domestic companies to challenge established players like Novo Nordisk and Eli Lilly, as several innovative drugs are in advanced clinical stages [6]. Future Outlook - The article emphasizes the commercial opportunity for domestic alternatives in the weight loss drug market, especially as imported drugs have already cultivated market demand [7].

此外，在市场配置方面，高盛维持对A股和港股的超配建议，预计沪深300目标点位为4600点，MSCI中 国指数的目标点位为84点，对应约10%的上行空间。行业方面，付思表示，高盛持续看好消费、银行、 房地产等对政策宽松敏感的行业。其中包括，消费相关的互联网消费服务，以及受益于政府消费的医疗 器械领域等。 她还观察到，本轮港股IPO热潮的基石投资者中，海外主权基金、养老金等长线投资者的参与度有所提 高。"它们的参与比例比之前要高，因为这轮赴港上市企业质地不错，吸引了一些长线资金参与。"付思 说。 整体而言，高盛认为，全球主流资金对中国资产的关注度显著升温。"我们明显感觉到，海外投资者对 中国市场的兴趣有所回暖，这从过去两个月我们的电话会、客户需求反馈等可以看出。"付思说。 在此背景下，高盛在近期提出了中国上市民企"十强新贵"概念，组成包括腾讯、阿里巴巴、小米、比亚 迪、美团、网易、美的、恒瑞医药、携程和安踏。 整体来看，这10家企业均为港股上市企业，多家是科技、消费、医药龙头。数据显示，目前，这10家公 司总市值达1.6万亿美元，在MSCI中国指数中的权重占42%。高盛预计，未来两年，这些企业盈利年均 复合增速将 ...

Core Viewpoint - The innovative pharmaceutical sector is experiencing a resurgence, driven by improved fundamentals, supportive policies, and increased market interest, particularly in the A-share and Hong Kong markets [1][3][12]. Group 1: Market Performance - The pharmaceutical sector has shown strong performance this year, with a notable rebound starting from April 9, despite recent pullbacks [1]. - The innovative drug segment in A-shares and Hong Kong stocks has continued to strengthen, indicating a recovery after four years of adjustment [1][3]. - The total amount of business development (BD) transactions for innovative drugs is projected to rise significantly, from $8.4 billion in 2020 to $51.9 billion in 2024 [4]. Group 2: Policy and Industry Trends - The policy environment has shifted from cost control to encouraging innovation, providing strong support for the development of innovative drugs [3]. - The number and quality of innovative drug products in China have significantly improved, leading to increased interest from foreign pharmaceutical companies [3][5]. - The penetration rate of innovative drugs in China is expected to rise, with current levels at around 20%, compared to 70%-80% in the U.S. [5]. Group 3: Investment Opportunities - Fund managers are optimistic about the future of innovative drugs, emphasizing the importance of technology and growth attributes in the sector [6]. - Investment strategies include focusing on high-quality companies, innovative drug leaders, and traditional pharmaceutical companies transitioning to innovative drugs [7][8][9]. - Investors can consider actively managed pharmaceutical funds or industry-themed ETFs to gain exposure to the innovative drug market [10][12]. Group 4: Fund Performance - Several funds managed by 工银瑞信 have demonstrated strong performance, ranking highly in their respective categories over various time frames [13][15]. - The 工银港股通创新药ETF has seen significant inflows, reflecting market preference for innovative drug companies [11].

Core Viewpoint - The recent performance of the Hong Kong pharmaceutical sector reflects a positive market sentiment towards innovative drug companies, driven by long-term expectations of industry upgrades and the recognition of R&D asset values [1][2]. Group 1: Market Performance - As of June 25, 2025, the CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index (930965) decreased by 0.64%, with mixed performances among constituent stocks [1]. - Notable gainers included Nuo Cheng Jian Hua (09969) up 1.48% and Yun Ding Xin Yao (01952) up 1.20%, while leading decliners included Lian Bang Pharmaceutical (03933) down 5.07% [1]. - The Hong Kong Pharmaceutical ETF (159718) saw a slight decline of 0.12%, with a recent price of 0.84 yuan, but had a weekly increase of 1.69% [1]. Group 2: Liquidity and Scale - The Hong Kong Pharmaceutical ETF had a turnover rate of 21.07% with a trading volume of 53.59 million yuan, indicating active market participation [1]. - Over the past week, the ETF's scale increased by 2.31 million yuan, ranking second among comparable funds [1]. - In terms of shares, the ETF added 5 million shares over the last three months, also ranking second among comparable funds [1]. Group 3: Industry Outlook - According to Fangzheng Securities, there is a strong belief in the ongoing bullish trend for innovative drugs, with a continued revaluation of innovative drug assets expected [1]. - The current market rally is characterized by a recognition of the commercial viability of innovative drug models, particularly for leading companies like BeiGene, Innovent Biologics, and Hansoh Pharmaceutical, which are anticipated to achieve profitability through business development or globalization by 2024 or Q1 2025 [1][2]. - The collective rise of leading innovative drug stocks indicates a systematic re-evaluation of their long-term R&D investments, with the market's confidence in the sustainability of their profit models improving [2]. Group 4: Fund Flows and Leverage - The Medical Innovation ETF (516820) experienced a 0.57% decline, with a recent price of 0.35 yuan, but had a 3-month cumulative increase of 2.05% [3]. - The ETF saw a net inflow of funds over the past six days, totaling 63.57 million yuan, with an average daily net inflow of 10.60 million yuan [3]. - Leveraged funds have been actively buying into the Medical Innovation ETF, with a total net purchase of 5.61 million yuan and a latest financing balance of 56.05 million yuan [3]. Group 5: Index Composition - The CSI Pharmaceutical and Medical Device Innovation Index (931484) includes 30 companies with strong profitability and growth potential, reflecting the overall performance of the pharmaceutical and medical device sector [5]. - The top ten weighted stocks in the index account for 66.57% of its total weight, including companies like Heng Rui Pharmaceutical and WuXi AppTec [5]. - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index (930965) also features a top ten weighted stock composition that represents 60.77% of the index, including companies like BeiGene and WuXi Biologics [6].

Group 1 - The Hong Kong IPO market has shown remarkable performance in the first half of the year, with 31 listings and a total financing amount of 884 billion HKD, surpassing the total financing of the previous year, making Hong Kong the global leader in IPO financing [1] - Institutional innovations have activated the financing momentum of the Hong Kong Stock Exchange, with optimized listing rules and improved approval efficiency being key drivers for attracting companies to list [2] - Leading companies in new economy and technology sectors have significantly contributed to Hong Kong's position as the top IPO financing venue globally, with major firms like CATL and Jiangsu Hengrui Medicine leading the way [2][3] Group 2 - The trend of A-share listed companies, especially in new economy and biomedicine sectors, seeking international development through Hong Kong listings is increasing, as the Hong Kong Stock Exchange responds to the demand for high-quality economic development [3] - The liquidity of the Hong Kong market has improved significantly, with a notable reduction in the price gap between H-shares and A-shares, enhancing the attractiveness of IPOs [4] - The continuous release of institutional dividends, the accelerated gathering of new economy industries, and the increasing convenience of cross-border capital flows are expected to strengthen Hong Kong's competitive advantage in attracting global new economy enterprises [4]

Group 1 - The China Strategic Emerging Industries Index (new emerging index, 000171) rose by 1.66% to 1188.03 points, with a trading volume of 110.449 billion yuan [1] - Over the past month, the index increased by 1.27%, while it decreased by 3.76% over the past three months and has fallen by 1.33% year-to-date [1] - The index includes 100 representative listed companies from sectors such as energy conservation and environmental protection, new generation information technology, biotechnology, high-end equipment manufacturing, new energy, new materials, new energy vehicles, digital creativity, and high-tech services [1] Group 2 - The top ten holdings in the index are BYD (8.72%), Dongfang Wealth (8.59%), Hengrui Medicine (5.81%), Zhongji Xuchuang (3.47%), Xinyi Sheng (3.3%), Haiguang Information (3.18%), Luxshare Precision (3.15%), WuXi AppTec (3.13%), Huichuan Technology (3.01%), and Northern Huachuang (2.61%) [1] - The market capitalization distribution of the index shows that 61.12% of the holdings are listed on the Shenzhen Stock Exchange, while 38.88% are on the Shanghai Stock Exchange [1] Group 3 - The industry composition of the index includes Information Technology (33.01%), Healthcare (15.20%), Communication Services (12.90%), Industry (12.37%), Consumer Discretionary (11.33%), Financials (9.11%), Materials (5.16%), Utilities (0.38%), Consumer Staples (0.31%), and Energy (0.24%) [2] - The index samples are adjusted biannually, with adjustments implemented on the next trading day after the second Friday of June and December [2] - Public funds tracking the new emerging index include Huaxia Strategic Emerging Index ETF Link A, Huaxia Strategic Emerging Index ETF Link C, and Huaxia Strategic Emerging Index ETF [2]

本次培训会上，有关中介机构引用境内A股企业赴港上市后，融资规模增长、海外市场份额提升等典型 案例，直观展现企业赴港上市的机遇与发展空间，旨在推动安徽省A股上市公司加快布局"A+H"双平 台，提升国际影响力和全球市场竞争力。 6月24日，安徽省委金融办联合人行安徽省分行、安徽证监局共同举办全省上市公司高质量发展专项培 训会，聚焦"A+H"上市、并购重组及再融资、科创债等话题，为辖区上市公司提供相关政策解读及业务 指导。 安徽省有关单位、各市地方金融管理职能部门、全省A股上市公司、省上市公司协会及长三角（安徽） 资本市场学院等260余名嘉宾参加本次培训会。 近一年多来，伴随着系列支持政策密集发布，内地企业赴港上市迎来黄金窗口期。新"国九条"出台后， 中国证监会发布5项资本市场惠港合作措施，明确表示将支持内地企业赴港发行上市。与此同时，香港 联交所陆续推出适用于生物医药企业上市的"18A"和新兴科技企业上市的"18C"等特殊上市规则，允许 公司以保密形式递交上市申请，并专门配套"科企专线"服务，为医药、科技企业在提交上市申请前提供 专门指引、解答关键问题，协助企业更有效率地筹备上市。 2025年以来，内地赴港上市企 ...

Investment Rating - The industry investment rating is maintained at "Outperform the Market" [3][82]. Core Viewpoints - The report emphasizes the significant progress of Chinese innovative drugs, highlighting their emergence as a global force in the pharmaceutical industry, supported by a solid industrial foundation, policy backing, and capital support [4][5]. - The gap between Chinese and global innovative drugs has narrowed significantly, with the time to market for first-in-class drugs reduced from over 10 years to within 1-5 years [4]. - The report indicates that Chinese companies now account for over 30% of global clinical trials, with more than 60% of popular targets being pursued by Chinese firms [35][38]. Summary by Sections Breakthrough Therapies - The development of innovative drugs in China is underpinned by a robust industrial base, supportive policies, and substantial capital investment, leading to rapid growth in the ADC market and next-generation therapies [4][12]. - Key drugs such as Keytruda and Semaglutide are projected to generate sales of $29.482 billion and $29.296 billion respectively in 2024, showcasing the potential of innovative therapies [4][12]. Achievements - Chinese innovative drugs have made significant strides, with the clinical trial participation rate increasing from 9.7% in 2016 to 28.2% in 2023 [35]. - The report notes that the number of Chinese companies involved in clinical trials for oncology drugs has risen from 15% in 2016 to 35.5% in 2023, indicating a strong focus on cancer therapies [35]. Leading Trends - The rapid growth of License Out transactions has provided substantial cash flow for innovative drug companies, facilitating their expansion into international markets [5][66]. - The report highlights that the Chinese market is still dominated by foreign patented drugs, but there is significant potential for domestic innovative drugs to capture market share, especially as many foreign drugs face expiration of patents [70][72].

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 江蘇恒瑞醫藥股份有限公司 呈交日期： 2025年6月24日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) 01276 | 說明 | H股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有 ...